ten23health®, a leading Swiss contract development and manufacturing organization (CDMO), has released its 2024 Fairstainability Report, showcasing significant advancements in sustainable pharmaceutical manufacturing.
The report underscores the company’s commitment to ambitious climate goals, validated by the Science Based Targets initiative (SBTi).
Key highlights
-
Significant Emissions Reduction: A 57% reduction in greenhouse gas emissions compared to the 2021 baseline, achieved one year ahead of schedule.
-
SBTi Validation: Confirmation of science-based climate targets, aligning with global efforts to limit warming to 1.5°C above pre-industrial levels.
-
My Green Lab Certification: The highest level of certification (Green) achieved by development laboratories in Basel.
-
Ecovadis Score: A score of 73, placing ten23health in the top 3% of companies assessed by EcoVadis in the manufacturing of pharmaceuticals.
ten23health is also the first sterile drug CDMO to achieve B Corp certification, demonstrating a commitment to social and environmental performance.
These achievements reinforce ten23health’s dedication to sustainability within the pharmaceutical sector. With a production site in Viège, ten23health exemplifies how pharmaceutical manufacturing can be both innovative and environmentally responsible.
ten23health’s impact in Valais
ten23health’s connection to Valais is primarily through its pharmaceutical production activities in the region, particularly in Viège.
Key aspects of this connection include:
-
Establishment and expansion in Viège: Construction of advanced facilities, including the VIVA2 plant inaugurated in 2024, enabling the production of over 30 million units annually (syringes, vials, cartridges) with sustainable technologies like photovoltaic panels.
-
Acquisition of swissfillon: Acquisition of Valais-based Swissfillon in 2021, specializing in sterile filling of complex pharmaceuticals, integrating development and production services in the region.
-
Job creation and economic impact: Successive expansions have generated over 100 additional jobs in the canton, reinforcing Valais as a center of excellence in life sciences and attracting international investment.
These achievements reinforce ten23health’s dedication to sustainability within the pharmaceutical sector. With a production site in Viège, ten23health exemplifies how pharmaceutical manufacturing can be both innovative and environmentally responsible.
Source : ten23health®
